Skip to main content

Day: November 9, 2025

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Super One Planned to Enter the Pilot Build and Production Phase at its Hanford Manufacturing Facility as First Batch of Complete Sets of Parts Scheduled to Arrive in the U.S. as Early as this Month

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor UpdateFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Super One Planned to Enter the Pilot Build and Production Phase at its Hanford Manufacturing Facility as First Batch of Complete Sets of Parts Scheduled to Arrive in the U.S. as Early as this Month.FF Recently Filed a Utility Patent Application for a Blockchain-and-Web3-Based Car Sharing and Short-Term Rental System.FF is scheduled to report its third quarter financial results for 2025 after market close on Thursday, November 13, 2025, and will hold an earnings call at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) that same day.LOS ANGELES, Nov. 09, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”),...

Continue reading

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular...

Continue reading

RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024 Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the third quarter of 2024, an increase of 15.2%; Digital Health reportable segment Adjusted EBITDA(1) increased 6.9% to $3.5 million in the third quarter of 2025 from $3.2 million in the third quarter of 2024 Total Company Adjusted EBITDA(1) margins increased by 26 bps to 16.2% in the third quarter of 2025 as compared with 16.0% in the third quarter of 2024 Adjusting for unusual or one-time items...

Continue reading

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular eventsHeartflow Plaque Staging Personalizes Individual Cardiac Risk*Heartflow Plaque Analysis is an FDA-cleared device. Heartflow Plaque Staging is an investigational only framework and its safety and effectiveness have not been reviewed by the FDA.Overall Considerations3. Tzimas, et al. JACC. 2023. https://doi.org/10.1016/j.jcmg.2023.05.011NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025. The new data add to the...

Continue reading

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD – The Liver Meeting® 2025

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025. In an oral presentation titled “Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline,” Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Professor of Hepatology and Consultant Hepatologist at the Institute of Liver Studies at King’s College Hospital in London, will be sharing results showing that treatment with ALXN1840 (tiomolybdate...

Continue reading

CNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025

CNH FLEETPROCNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025CNH introduces FLEETPRO aftermarket line-up at Agritechnica 2025A new spare parts and consumables certified portfolio Precision Technology service kit updatesHanover, November 9, 2025 CNH (NYSE: CNH), a global leader in agricultural equipment, technology and services, is introducing its FLEETPRO line-up of aftermarket services at Agritechnica 2025. The FLEETPRO line-up includes a portfolio of certified spare parts and consumables for agricultural equipment, mainly recommended for post-warranty and legacy agricultural machinery. This delivers customers with additional support by providing dependable performance and tailored dealer support at a competitive price point. It is available across Europe, the Middle East, and Africa (EMEA). An enhanced...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.